With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CE — frequently asked questions
Is Celanese Corporation overvalued?
In our latest published analysis dated 2026-10-17, CE looks meaningfully undervalued. The price recorded at analysis is USD 47.5 versus our fair value of USD 76.3; the high endpoint is presented separately as potential value of USD 102. That implies roughly 60.7% upside to fair value at that date.
Our latest published report, analyzed 2026-10-17, gives CE a fair value of USD 76.3 and a potential value of USD 102. The conclusion is triangulated across multiple valuation models and weighted by reliability for Celanese Corporation's archetype; it is a dated research output, not a live price.
Should I buy CE now?
Our latest published rating for CE, analyzed 2026-10-17, is Strong Buy. Celanese Corporation looks meaningfully undervalued at the analysis-date price of USD 47.5 versus fair value of USD 76.3; potential value is USD 102. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CE?
The dedicated bear-case section in our report analyzed 2026-10-17 documents Celanese Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CE's rating?
Our latest published rating for CE, analyzed 2026-10-17, is Strong Buy, with a published moat assessment of 6.5/10 (Narrow). It reflects our fair value of USD 76.3, the potential value of USD 102, and the price recorded at analysis (USD 47.5).
Mid-cycle earnings recovery driven by Engineered Materials footprint optimization (> $50M annualized fixed-cost savings), durable Acetyl Chain profitability, and rapid debt reduction funded by $700M-$800M in annual free cash flow and $1B in asset divestitures, driving an equity multiple re-rating from 7.18x forward P/E toward specialty chemical peers (EMN at 9.35x).
Main risk
Free cash flow falling below $400M annually triggered by a synchronized commodity chemical downcycle and protracted automotive build contraction.
Celanese Corporation (NYSE: CE) presents a compelling cyclical turnaround opportunity. The stock trades at $47.49 as of October 16, 2026, representing a 37.8% discount and +60.7% implied upside to the house fair value midpoint of $76.31, supporting an affirmed Strong Buy committee rating. Robust cash generation from the Acetyl Chain and aggressive operational restructuring in Engineered Materials provide a clear path to balance-sheet deleveraging and substantial equity value re-rating.3
The current valuation reflects extreme trough sentiment. In FY2025, Celanese reported a GAAP net loss of -$1,165M and an operating loss of -$786M on net sales of $9,544M, weighed down by $1,513M in non-cash asset impairments across Engineered Materials. Despite these accounting charges, operational cash flow held up remarkably well, delivering $1,146M in operating cash flow and $803M in free cash flow ($773M after noncontrolling interest distributions).5,6
Operating performance has inflected powerfully following the cyclical trough. Celanese demonstrated strong sequential pricing and volume recovery across both core operating divisions. The Acetyl Chain captured expanding unit margins driven by its low-cost Western feedstock advantage and robust downstream derivative pricing. Concurrently, Engineered Materials demonstrated resilient customer demand and disciplined pricing execution across specialized applications, reversing prior-year destocking pressures and restoring underlying operating profitability.
Balance-sheet deleveraging is the primary catalyst. Management affirmed full-year FY2026 free cash flowguidance of $700M-$800M and adjusted EPS of approximately $6.00. With $1,364M in cash and cash equivalents, Celanese reduced total debt by $591M in 1H 2026 to $12,007M. Progress on the $1B divestiture target ($500M completed via Micromax) and >$50M of annualized fixed-cost savings from closing the Ulsan compounding plant, rationalizing nylon 6,6, and exiting the Lanaken facility establish an aggressive debt reduction runway. Trading at just 7.18x forward earnings, Celanese offers exceptional risk-adjusted upside as mid-cycle profitability is restored.3,4
Durable Low-Cost Acetyl Advantage
Celanese's world-scale integrated acetyl facilities in North America leverage low-cost feedstocks to capture premium pricing, generating durable cash flow and resilient operating margins across global supply chains.
Engineered Materials Operational Turnaround
Following substantial non-cash asset impairments, core operational profitability is recovering as footprint rationalization and manufacturing site closures unlock permanent annualized fixed-cost reductions.
Rapid Deleveraging Runway
All surplus cash flow ($700M-$800M guided FY2026 FCF) and $1B in asset sales ($500M completed) are dedicated to reducing the $12.40B debt load, transferring value directly to equity.3,4
House recommendation
Affirmed Strong Buy. The market prices Celanese as an impaired credit story, overlooking proven free cash flow generation ($803M in FY2025, $700M-$800M guided for FY2026) and operational inflection in both segments. With intrinsic fair value at $76.31 versus $47.49 market price, risk-adjusted return heavily favors aggressive capital commitment.3,4,5
Company overview
Celanese Corporation is a global chemical and specialty materials leader producing engineered polymers and acetyl products used across automotive, medical, electronics, consumer goods, and industrial applications. The company operates two principal segments: Engineered Materials and the Acetyl Chain. In FY2025, Celanese generated $9,544M in consolidated net sales, with Engineered Materials contributing $5,390M and the Acetyl Chain contributing $4,232M.
Celanese maintains leading global market positions in acetic acid, vinyl acetate monomer (VAM), polyoxymethylene (POM), and engineered nylon compounds. Its competitive foundation combines low-cost upstream acetyl manufacturing assets in the Western Hemisphere with deeply integrated customer specifications in high-performance polymer applications.
The stress test models a simultaneous deterioration across end markets and capital access: global automotive build weakness depressing Engineered Materials demand, an influx of Chinese acetic acid eroding Acetyl Chain margins, and credit spreads widening. In this compound shock, free cash flow contracts below the $400M danger threshold compared to the $700M-$800M guidance range. Celanese would face severe liquidity friction addressing $1,311M of short-term borrowings while carrying $12,396,999,680 of total debt. This stress environment increases pre-tax cost of debt beyond the current 19.64%, forcing painful non-core asset sales at depressed valuations and dilutive equity interventions.
Celanese derives its narrow economic moat from two structural foundations: an unassailable global cost advantage in the Acetyl Chain and high customer switching costs in Engineered Materials. The Acetyl Chain leverages massive integrated assets in North America and Asia, securing low-cost natural gas and methanol feedstocks to deliver industry-leading conversion economics. In FY2025, despite cyclical headwinds, the Acetyl Chain produced $539M in operating profit on $4,232M in revenue. In Q2 2026, the segment demonstrated its commercial agility by capturing Western Hemisphere pricing opportunities, driving net sales to $1.33B (+28% QoQ) and adjusted EBIT to $321M at a 24.2% margin.
In Engineered Materials, competitive advantage arises from deeply embedded customer specifications. Its high-performance polymers are engineered directly into mission-critical automotive components, medical devices, and electronics, where substituting materials requires lengthy OEM re-certification and substantial regulatory friction. Although Engineered Materials generated an operating loss of -$958M in FY2025 due to $1,513M of non-cash impairment charges, core operational profitability rebounded sharply in Q2 2026, delivering $156M in operating profit and $234M in adjusted EBIT (16.2% margin) on $1.45B in net sales.
The highlighted cell is Fair value when every assumption sits at its base level ($76.31). Each row and column shows what Fair value becomes when one assumption moves.
Operating margin expands toward double-digit levels by FY2028, driven by accelerated nylon portfolio synergies and automotive build recovery.
§7 Earnings decision tree
Beat
Maintain Strong Buy; Preserve core allocation; verify that robust quarterly free cash flow translates directly into accelerated debt retirement and lowers short-term borrowings.
Trigger: Adjusted EPS exceeding the upper bound of Q3 guidance and quarterly free cash flow exceeding management expectations.
A beat demonstrates faster realization of nylon portfolio synergies and stronger Western Hemisphere acetyl pricing power, accelerating balance-sheet deleveraging.
In-line
Maintain Strong Buy; Maintain established allocation; monitor execution on the Lanaken closure and track inventory destocking in Engineered Materials.
Trigger: Adjusted EPS within the guided range of $1.35 to $1.75 for Q3 2026 and FY2026 adjusted EPS tracking ~$6.00.
The global chemical sector has endured a multi-year destocking downturn marked by elevated European energy expenses, weak automotive build rates, and widespread earnings compression. Celanese absorbed $1,513M in asset impairments in FY2025 and reported an operating loss of -$786M, while chemical peers experienced broad margin contraction (Dow operating margin 11.59%, Mosaic operating margin -0.12%). Rationalization is accelerating across the sector, with Celanese closing compounding in Ulsan, South Korea, optimizing nylon 6,6, and targeting the Lanaken, Belgium facility for closure.4,6
Bull cycle
During a synchronized cyclical expansion, global automotive build recovery and consumer electronics demand accelerate volume growth for POM and nylon 6,6, while supply tightening in acetic acid and VAM drives substantial spread expansion. Celanese's low-cost US Gulf Coast asset base allows massive operational leverage, generating surplus cash to rapidly pay down debt and re-rating the multiple toward historical mid-cycle averages.
Bear cycle
In a downcycle continuation, persistent weakness in global automotive assemblies, protracted European industrial stagnation, and aggressive export competition from unconstrained Chinese chemical capacity keep acetyl spreads compressed and engineering resin utilization low. Elevated energy costs in Europe would force extended plant idling, while high interest burdens prevent meaningful debt retirement.
§11 Position management
Sizing
3-5%
High conviction is supported by the massive +60.7% implied return to fair value midpoint ($76.31) from $47.49, proven operational turnaround in Q2 2026, and affirmed FY2026 FCFguidance of $700M-$800M. Sizing is moderated to 3-5% to account for high financial leverage ($12.40B total debt).3,4
Risk
Given Celanese's substantial total debt obligations and elevated cost of capital, overall portfolio exposure must be strictly constrained. Investors should monitor macro chemical spread developments, bond yield movements, and automotive OEM build rates, trimming exposure if quarterly operating cash flow weakens substantially.
§12 Investor perspectives
Deep Value & Cyclical Turnaround
Buy
Trading at 7.18x forward earnings and a 37.8% discount to intrinsic fair value of $76.31, Celanese offers an asymmetric +60.7% upside opportunity as cyclical trough margins recover toward normalized mid-cycle levels.3
Institutional Quality & Deleveraging
Buy
The dedication of all free cash flow ($700M-$800M guided FY2026) and $1B in asset divestitures directly reduces leverage and transfers enterprise value from debt holders to equity owners.4
Credit & Downside Risk Perspective
Hold
Investors with strict low-leverage mandates should monitor maturities and verify that full-year securely achieves targeted thresholds before expanding exposure.
§14 Final recommendation
Action
Strong Buy
Celanese Corporation represents an exceptional cyclical turnaround investment opportunity with an affirmed Strong Buy rating. Fair value is established at $76.31 with Potential value of $102.27, providing 60.7% upside from $47.49. The operational rebound demonstrates resilient underlying cash generation and disproves market fears of structural deterioration.3
With management guiding to $700M-$800M in FY2026 free cash flow, $1B in planned asset divestitures ($500M already closed), and > $50M in structural footprint savings, the business is poised to aggressively reduce its $12.40B total debt burden. This debt reduction will drive an equity re-rating from the current depressed forward P/E of 7.18x toward normalized peer valuation.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-17 · Published 2026-10-17 · Provider-adjusted · cited for 3 figuresCited in Earnings decision tree
Protracted automotive assembly weakness, persistent raw material cost inflation, and aggressive export competition from unconstrained Chinese chemical capacity delay operating recovery in Engineered Materials and compress acetyl spreads. Under-absorption penalties and elevated debt service consume operating cash flow, delaying balance-sheet deleveraging.
Ways this thesis can break
Severe automotive production downturn and rising feedstock costs depress consolidated operating margin below expectations.
CEO Richardson confirmed auto builds were down year-over-year in Q2 2026, raw materials escalated in Engineered Materials, and footprint actions impose a $45M inventory under-absorption penalty in 2H 2026. A breach below 6.0% consolidated operating margin induces a -24.5% fair value shock.4
Celanese total debt stands at $12,396,999,680, debt weight is 70.4%, pre-tax cost of debt is 19.64%, and forward P/E is 7.18x. A multiple de-rating below 6.8x reduces fair value by -20.0%.2,3
FV impact
-4.3%
Terminal multiple 20% lower
Trigger
Credit rating downgrade or refinancing friction drives up the cost of capital.
With pre-tax cost of debt at 19.64% and total debt of $12,396,999,680, any bond spread widening will drive up refinancing costs on $1,311M of short-term borrowings, pushing WACC above 17.29% and driving a -31.8% fair value reduction.2,3
FV impact
-20.7%
Cost of capital 2 points higher
Trigger
Within 12 months
Synchronized commodity chemical downcycle and failed EM turnaround trigger a liquidity crunch.
Management highlighted moderation in 2H 2026, acetate tow destocking, and automotive weakness. If free cash flow falls below $400M versus the guided $700M-$800M, Celanese will fail to cover short-term debt of $1,311M, triggering a -42.5% fair value collapse.4
FV impact
-2%
The analyst's bear scenario path and multiple as the base case
Trigger
Within 24 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
Global acetic acid capacity expansion and Chinese export competition erode Western Hemisphere pricing premiums, impairing the primary cash-generating engine.
Current:24.2% in Q2 2026; 12.6% in Q1 2026 and 16.4% in FY2025
Management's ongoing portfolio restructuring bolsters these structural advantages. The business completed the closure of its Ulsan, South Korea compounding plant, transitioned volume to larger, lower-cost facilities in China and India, and finished the nylon 6,6 network optimization ahead of schedule. Alongside the planned closure of the Lanaken acetate tow plant, these actions will generate over $50M in annualized fixed-cost savings, cementing Celanese's positioning at the low end of the industry cost curve.
In FY2025, Celanese generated an adjusted ROIC of 6.2% against a computed WACC of 15.29%, reflecting negative economic profit during a cyclical trough compounded by $1,513M of non-cash asset impairments. As normalized operating income recovers from -$786M in FY2025 to $749M in FY2026 and $907M in FY2027, and total debt of $12,396,999,680 is aggressively paid down via $700M-$800M in annual free cash flow, ROIC is projected to expand toward the moderate cost of equity of 8.40%.2,3,4,6
6.5/ 10
Narrow
Sources of advantage
01Cost Advantage in Global Acetyl Chain via Integrated Scale and Raw Material Access — Celanese operates a globally integrated acetyl network with world-scale, low-cost production of methanol, acetic acid, and downstream derivatives such as VAM and emulsions. The business achieved $539M of operating profit in FY2025 and delivered $321M of adjusted EBIT at a 24.2% margin in Q2 2026, supported by commercial agility and flexible swing assets like the Frankfurt VAM facility.Wide
02High Customer Switching Costs in Specified Engineering Polymers — Engineered Materials supplies highly specialized polymer formulations (POM, nylon 6,6, UHMW-PE) that require extensive technical OEM qualification across automotive, medical, and electronics applications. Even with automotive builds declining in Q2 2026, the segment implemented 6% sequential price increases and achieved adoption of POM ECO-C in automotive fuel pump modules and EV drive units.Moderate
Feedstock and Energy Cost Inflation across European and Asian Manufacturing Assets
medium
6-18 months
Dynamic production dispatch at the Frankfurt VAM unit, closure of the Lanaken facility, and transitioning Asian compounding to larger, lower-cost facilities in China and India.4
Global Acetic Acid Capacity Additions and Chinese Export Competition
medium
12-24 months
Leveraging downstream integration into higher-margin derivatives (VAM, emulsions, acetate tow) and capitalizing on supply reliability in the Western Hemisphere.4
Strategic diversification into high-growth medical and electronics applications alongside >$50M of annualized fixed-cost reductions across nylon and acetate tow assets.4
Consolidated EBIT margin normalizes from 7.43% in FY2026 to 9.04% in FY2027 and 10.18% in FY2028.
Acetyl Chain generates durable, high-teens adjusted EBIT margins through global cost advantage.
Annual free cash flow averages $700M-$800M, with $1B in total divestitures achieved by end of 2027.4
Terminal P/E multiple of 8.5x applied, reflecting conservative positioning relative to peers.
Celanese executes on its core operational strategy: modest revenue growth, steady recovery in Engineered Materials margins via footprint actions, and resilient cash generation from the Acetyl Chain. Free cash flow is disciplined and deployed exclusively to debt reduction, steadily lowering financial leverage and driving intrinsic value convergence to $76.31.
Performance within guidance validates that the business is successfully navigating the anticipated 2H 2026 moderation and the $45M inventory under-absorption headwind while remaining on track for full-year FCF of $700M-$800M.
Miss
Downgrade the rating; Pause incremental capital deployment; re-examine debt covenant headroom and verify that annual free cash flow remains safely above liquidity stress thresholds.
Trigger: Adjusted EPS falling below the lower bound of Q3 guidance or full-year free cash flow tracking below reaffirmed targets.
A miss indicates that raw material inflation or automotive build declines are overwhelming pricing power, stalling deleveraging and raising debt service pressure on $12.40B in total debt.
Reported earnings quality is underpinned by substantial cash conversion, defined as the business's ability to generate cash from operations relative to reported operating income, and genuine structural restructuring. The spread between GAAP results and adjusted operating figures reflects discrete exit and shutdown costs from closing the Ulsan compounding plant, rationalizing the nylon network, and idling the Lanaken facility. These cash outlays deliver permanent fixed-cost reductions rather than recurring operational expenses. Robust operational cash generation relative to earnings and sustained free cash flow confirm resilient underlying earnings durability.
Estimate momentum
Consensus estimates have stabilized following the Q2 2026 earnings release on August 4, 2026. FY2026 consensus EPS moved modestly from $6.05 pre-event to $6.11 post-event before settling at $5.97 as of October 17, 2026. For FY2027, consensus EPS sits at $6.15 (range $4.94 to $6.75 across 16 contributors). Revenue estimates are similarly steady at $10.01B for FY2026 and $9.95B for FY2027, reflecting balanced expectations as market participants weigh 2H moderation against restructuring benefits.1
Metrics to watch into the print
01
Metric:
Progress on Portfolio Divestiture Program
CurrentApproximately $500M achieved following the Micromax transaction; actively marketing additional portfolio assets to deliver the remaining $500M by end of 2027.
Why it matters
Asset sales provide direct non-operational cash proceeds to accelerate debt reduction and de-risk the balance sheet.
02
Metric:
Engineered Materials Footprint Rationalization and Cost Savings
CurrentUlsan plant closure and nylon 6,6 network optimization completed ahead of schedule in Q2 2026; Lanaken closure proceeding toward target.
Why it matters
Footprint actions will generate >$50M in annualized fixed-cost savings once temporary $45M inventory under-absorption headwinds clear in 2H 2026.4
Cash flow generation remains robust despite cyclical trough conditions. Celanese generated $1,146M in cash provided by operating activities in FY2025 and $803M in free cash flow ($773M after noncontrolling distributions). In 1H 2026, operating cash flow reached $285M ($209M in Q2 2026) and free cash flow reached $143M ($140M in Q2 2026), reflecting seasonal working capital build from higher revenue and prices. Management affirmed full-year FY2026 free cash flow of $700M-$800M, supported by working capital releases in 2H and structural inventory reductions in Engineered Materials.4,5,6
Celanese's capital allocation hierarchy is completely centered on debt reduction. Organic capital expenditures are strictly disciplined at $340M-$360M annually ($343M in FY2025; $62M in Q2 2026), well below annual depreciation of ~$750M. The quarterly dividend has been preserved at a modest level ($0.12 per share), while share repurchases remain entirely suspended. Management has committed all excess free cash flow ($700M-$800M guided FY2026) and divestiture proceeds ($1B target, $500M completed) to pay down debt, de-risking the capital structure.
Adjusted ROIC of 6.2% in FY2025 reflected cyclical trough conditions, depressed operating margins (-8.24% GAAP), and goodwill impairments. Q2 2026 operational performance ($276M operating profit, $470M adjusted EBIT) confirms an upward trajectory as operating margins normalize and invested capital shrinks through debt repayment.
Adjusted ROIC of 6.2% in FY2025 trailed computed WACC of 15.29%, which is inflated by Celanese's 70.4% debt weighting and 19.64% pre-tax cost of debt. As normalized EBIT rises to $749M in FY2026 and $907M in FY2027 and debt is paid down, ROIC is projected to surpass the moderate cost of equity of 8.40%.
Engineered Materials Inflected to Profitability in 1H 2026 Post-Impairment
Engineered Materials reported an operating loss of -$958M in FY2025, but rebounded to $156M in operating profit and $234M in adjusted EBIT (16.2% margin) in Q2 2026 driven by 6% pricing realization.
The operational turnaround in Engineered Materials is functioning, restoring core segment margins ahead of the full realization of footprint restructuring benefits.
Acetyl Chain Functions as an Agile Cash Generation Machine
Acetyl Chain produced $539M in operating profit in FY2025 and generated $237M in operating profit ($321M adjusted EBIT, 24.2% margin) in Q2 2026 on 22% sequential price gains.
Global asset network integration and low-cost feedstock access provide an indispensable cash generation engine during broader cyclical turbulence.
Aggressive Deleveraging Directly Reallocates Value to Equity Holders
Celanese carries $12,396,999,680 in total debt ($12,007M reported at Q2 2026, down from $12,598M at year-end 2025), driving $186M in quarterly interest expense and a 19.64% pre-tax cost of debt.
Every dollar of free cash flow and divestiture proceeds applied to debt paydown yields an immediate reduction in interest expense, expanding equity value.
Celanese Corporation (CE) trades at 7.2x forward earnings against a peer median of 11.7x. Its EV/EBITDA of 9.9x compares with a peer median of 9.1x. The comparison uses 4 peers: Dow Inc., The Mosaic Company, Eastman Chemical Company and Corteva Inc., as of 2026-10-17.
Secular trends
Trend
Impact
Note
Automotive Electrification and Lightweighting
positive
Global OEM transitions to electric powertrains require high-specification polymers with specialized thermal, electrical, and structural characteristics, driving penetration in electric drive units and battery components.
Demand for Bio-Based and Low-Carbon Materials
positive
Industrial customers are prioritizing reduced carbon footprints, accelerating commercial adoption of Celanese POM ECO-C in automotive applications and bio-based ethyl acetate with partners like Siegwerk.
Regional Energy Cost Advantage in North America
positive
Structural natural gas cost advantages in North America provide Celanese's US Gulf Coast acetyl production with a persistent cost moat over high-cost European and Asian producers.
Positioning
Celanese is positioned as an agile, low-cost survivor at the trough of the cycle. While broader industry capacity data remains evidence-limited and demand-led, Celanese's strategic flexibility is demonstrated by its ability to swing production at the Frankfurt VAM unit based on regional demand dynamics, maintain reliability of supply across Europe and the Americas, and execute targeted cost restructuring that lowers break-even operating levels.4
Entry tranches
Level
Action
Why
$47.49
Initiate core allocation representing the primary tranche of target position
Shares trade at $47.49, offering 60.7% upside to Fair value of $76.31 with compressed forward multiples reflecting cyclical trough sentiment.
Below $47.49
Add second tranche on cyclical pullback
Exit tranches
Level
Action
$76.31
Trim partial position and recover initial principal
$102.27
Exit remaining position as shares approach the upper valuation bound
Free cash flow falling below $400M annually triggered by a synchronized commodity chemical downcycle and protracted automotive build contraction. Inability to generate cash from operations forces Celanese to refinance $1,311M of short-term borrowings at punitive market rates (pre-tax cost of debt already 19.64%), driving WACC above 17.29% and consuming operating cash. Deleveraging stalls across the $12.40B total debt burden, prompting debt rating downgrades, terminal multiple compression, and a -42.5% fair value reduction. Free cash flow generation tracking below $100M per quarter or full-year FCF failing to achieve the $700M-$800M guidance range.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
